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Abstract
It was previously thought that the RNA structural elements within the 5’UTR were
the sole determinants of RNA packaging in HIV-1. However, in 2013 Chamanian et al.
discovered that the region overlapping the Ribosomal Frameshift Signal (RFS) acted to
enhance RNA packaging 50 fold and was thus named the genomic RNA packaging enhancer
element (GRPE). To determine if the GRPE was conserved across lentiviruses, using the
same approach as Chamanian et al., deletions in similar regions of the SIVmac239 and FIV
34TF10 genomes were done to measure their impact on RNA packaging. No region across
the gag-pol ORF of SIVmac239 had any impact on RNA packaging, and the deletion of the
RFS in FIV 34TF10 had no impact either, although the RRE was disposable in the
SIVmac239 system but necessary in FIV34TF10. This study shows that the GRPE is likely
specific to HIV-1.
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Chapter 1

1

« Introduction »

1.1 « HIV-1, The Causative Agent of AIDS »
In 1981, physicians in New York and San Francisco were puzzled after 41
homosexual men were diagnosed with a rare form of cancer known as Kaposi’s sarcoma
1.

Nine of these patients were tested and discovered to have severe immune defects,

specifically with their B and T cell lymphocytes. Initially thought to be a disease specific
to the gay population, the immunodeficiency was referred to as Gay Related
Immunodeficiency but then renamed to Acquired Immunodeficiency Syndrome (AIDS)
since females and heterosexuals in Africa were being diagnosed with a similar
immunodeficiencies that led to opportunistic infections 2. Researchers began taking
samples from these patient groups to identify the agent causing these diseases. By 1984,
Luc Montagnier and Robert Gallo independently identified the virus causing AIDS,
which ultimately became known as Human Immunodeficiency Virus (HIV) 3,4. HIV was
found to preferentially infect CD4+ T helper cells, and over time a depletion of the
body’s CD4+ T cell count cripples the immune system, making the patient infected
susceptible to secondary co-infections that could prove to ultimately be fatal5.
Over thirty years have passed since the identification of HIV and there is still no
vaccine or functional cure. In that time, AIDS has been responsible for over 35 million
deaths, and at the end of 2016 the WHO reported that 36.7 million people were currently
infected with HIV. Thankfully, the development of antiretrovirals has helped suppress
viral replication and prevent progression towards AIDS but these drug regimens aren’t
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always available to the majority of those infected with the virus and drug resistance still
remains an issue. Therefore, scientists continue to investigate the different parts of the
replication cycle and compare and contrast that with related viruses to try to identify new
targets for treatment and eradication.

1.2 « Retroviruses»
HIV is a Lentivirus, which falls under the Retroviridae family. Retroviruses are
enveloped viruses that contain two copies of positive sense single stranded RNA. The
earliest discoveries of retroviruses date back to the beginning of the 20 th century when
different groups were able to identify viruses responsible for leukosis and sarcomas in
avian species6. Perhaps the most important discovery in the field of retrovirology was
made in 1970 when Howard Temin and David Baltimore both identified a protein unique
to retroviruses that is able to convert single stranded viral RNA into double stranded
DNA7,8
Temin had proposed a theory that Rous Sarcoma Virus (one of the first identified
retroviruses) replicated through a DNA intermediate step, and although many had
initially doubted his “provirus” theory, the discovery of reverse transcriptase confirmed
it. Upon virus entry, reverse transcriptase is able to synthesize proviral DNA from the
viral RNA, which is subsequently integrated into the host chromosome. Integration into
the host cell genome is a hallmark of retroviral infection and contributes to its ability to
establish latently infected cells, leaving a patient asymptomatic for long periods of time
post infection9. This characteristic latent period of infection was seen in patients that were
diagnosed with AIDS which is the reason Gallo and Montagnier decided to look for a
retrovirus.
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Retroviruses can be classified as either simple retroviruses or complex
retroviruses based on their genome’s protein coding capacity. Simple retroviruses contain
three open reading frames (ORFs) necessary for encoding the Gag, Pol, and Env genes
and are further subdivided into alpharetroviruses, betaretroviruses and
gammaretroviruses. In addition to gag, pol and env genes, complex retroviruses are also
able to code for accessory genes that aid in pathogenesis and immune evasion. The
complex retroviruses can be further subdivided into deltaretroviruses, epsilonretrovirus,
spumaviruses and lentiviruses10.

1.3 « Lentivirus Evolution»
It comes as no surprise that HIV is the most studied retrovirus due to its
devastating effects on the infected human population, but researchers continue to study
other lentiviruses to be able to better understand the virus’s evolutionary past as well as
develop other animal models to test treatments.
The most abundant strain of HIV and the strain responsible for the epidemic is
HIV-1. These HIV-1 strains are further subdivided into groups M, N, O and P, with
group M making up the vast majority of human infections 11. A second, less pathogenic,
strain of HIV has also been discovered in humans named HIV-2. HIV-2 is less
transmissible than HIV-1 and patients infected with HIV-2 typically have a much slower
rate of CD4+ T cell decline as well as reduced viral loads in their blood.
The evolutionary past of HIV can be traced back to its closest relative, the Simian
Immunodeficiency Virus (SIV)12. It is believed that HIV evolved through zoonotic
transmission of SIV from non-human primates due to bush meat hunting in sub Saharan
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Africa. The closest simian relative of HIV-1 was first discovered in two chimpanzees that
were in captivity and was named SIVcpz. Further studies confirmed that SIVcpz was the
source for the zoonotic transfer of SIV to humans, specifically the subspecies Pan
troglodytes troglodytes12. Interestingly, SIVcpz does not typically progress to
AIDS13.The origin of HIV-2 however, has been tracked to another independent zoonotic
transfer, from SIV infected Sooty Mangebys in West Africa (SIVsm) 14. These SIVsm
infected primates also did not produce AIDS like symptoms however a closely related
virus was identified in captive macaques in which the molecular clone, named
SIVmac239, results in AIDS and is now used in the majority of macaque studies. The
discovery of this virus has been crucial for animal studies since an AIDS like phenotype
in non human primates is necessary to be able to gauge the efficacy of a certain
treatments and vaccines.
Although SIV is the closest lentivirus relative to HIV, other lentiviruses that
infect mammals, including cows, sheep, horses and cats, are also the subject of extensive
research15. Feline Immunodeficiency Virus (FIV) is one such lentivirus and also causes
an AIDS like phenotype in domestic cats across the world 16. The transmission of FIV is
typically through transfer of blood during cats fighting. Recent studies have been tackling
the idea of using FIV as another model for vaccine and treatment testing as well as a
vector for gene delivery in human cells, therefore understanding the molecular pathways
of FIV can also be of great benefit to HIV research and treatment17,18.
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1.4 « Lentivirus Genome»
Lentiviruses like all other retroviruses contain gag, pol and env, but it is their
additional accessory genes that allow them to evade the immune system and ultimately
progress to AIDS (Figure 1). The first open reading frame in the lentivirus genome
belongs to the group specific antigen or gag. Gag is translated from the full length
unspliced mRNA as a polyprotein in lentiviruses and provides the structural proteins
necessary for the assembly of viral particles. In HIV-1, Gag is synthesized as a 55kd
polypeptide that contains 4 major subdomains and two spacer regions 19. At the 5’ end of
the Gag polyprotein is the matrix protein (MA). The matrix protein contains a 5’
myristoylation site that is able to interact with phosphatidylinositol-4,5-bisphosphate
(P45B) on the inner side of the cell’s plasma membrane20. This interaction is responsible
for targeting gag to the plasma membrane for virus assembly and budding. FIV matrix is
very similar to that of HIV and SIV, in that it is also myristoylated and binds to P45B at
the plasma membrane to initiate viral assembly21. The next lentiviral subdomain of gag is
the capsid domain (CA), which is responsible for the formation of the bullet shaped viral
core. In HIV-1 and FIV, CA is 24kDa and thus referred to as p24, while in SIV it is
slightly larger and referred to as p27, but all behave in a similar manner22,23. CA contains
two helical domains, one at each N terminal and C terminal end. The C terminal domain
of CA contains a dimer interface that allows for the multimerization of gag to initiate
viral core assembly24 . The C terminus of MA contains an -helix that is able to interact
with the N terminal domain of CA to target the viral core to the plasma membrane for the
assembly and maturation of viral particles20. Downstream of CA, is the nucleocapsid
(NC) domain of Gag which contains two zinc finger domains which are able to bind
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genomic RNA and target it for genomic RNA encapsidation25. The final major
subdomain of the gag protein in HIV and SIV is p6, a 6kDa protein necessary for the
recruitment of ESCRT machinery that is co-opted by the virus for budding of newly
synthesized particles26. FIV does not encode for p6 but contains a similar protein at the 3’
end of Gag known as p2 that is required for efficient budding at the viral membrane27,28.
Overlapping the 3’ end of the gag ORF is the beginning of the pol gene. Pol is
found in all retroviruses and encodes all the enzymatic proteins necessary for viral
replication 29. In HIV, SIV and FIV, Pol is synthesized as the Gag-Pol polyprotein when
the ribosome shifts into the -1 reading frame while translating the full length unspliced
mRNA30,31. The pol ORF begins with protease (PR) at the 5’ end. PR is autocatalytically
cleaved from the precursor Gag-Pol polyprotein and then forms a homodimer with
itself32,33. Once in its homodimeric form, PR is able to proteolytically cleave the Gag-Pol
polyprotein into its substituents during viral maturation after the virus has bud from the
cell membrane34. Both from a structural and functional standpoint, PR is fairly similar
between HIV, FIV and SIV35. The HIV and SIV Gag-Pol polyprotein contain similar
cleavage sites and can be cleaved by . FIV PR only has 23% amino acid identity with
HIV-1 and is not able to recognize and cleave HIV-1 Gag-Pol35.
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Figure 1 Schematic Representation of Lentiviral Genomes (A) HIV-1 (B) SIVmac239 (C) FIV 34TF10.
MA=Matrix, CA=Capsid, NC=Nucleocapsid, PR=Protease, RT=Reverse Transcriptase and IN=Integrase.
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The aforementioned reverse transcriptase (RT) is also within the pol gene. RT is
first produced as a 66kDa protein but then protease cleaves a 15kDa segment at the Cterminus to produce a 55kDa protein which forms the functional RT heterodimer with the
66kDa precursor3637. RT is able to convert viral RNA to DNA but with no proofreading
ability and a high error rate, resulting in a high mutation rate allowing the virus to evolve
at a faster rate and become resistant to treatments 7,8. After RT has created the double
stranded proviral DNA, the final protein in the pol gene, integrase (IN), is able to
translocate the DNA into the cell nucleus and facilitate the integration into the host
chromosome38,39. One gene that FIV contains but is lacking in primate lentiviruses is
dUTP diphosphotase (dUTPase) an enzyme that is capable of dephosphorylating dUTP,
but studies on the protein have been lacking and its function within the FIV lifecycle,
amongst other retroviruses, remains largely unknown40.
The final gene encoded in all retroviruses is the env gene that makes up the viral
glycoproteins on the virus envelope. In HIV, SIV and FIV, env contains two subdomains:
the surface (SU) glycoprotein (gp120 in primate lentiviruses and gp100 in FIV) domain
and the transmembrane (TM) glycoprotein (gp41 in primate lentivirus and gp50 in FIV)
domain41,42. The SU domain forms a trimer that is exposed on the surface of viral
particles and facilitates binding of the virus to host cell receptors. The TM domain forms
a heterotrimer with the SU domain and spans the cell membrane, with a cytoplasmic tail
that extends into the cell cytosol43. Env is synthesized as a precursor protein in the rough
endoplasmic reticulum where it forms trimers and becomes heavily glycosylated as it
moves through the Golgi complex towards the cell membrane. As gp160 (HIV, SIV) or
gp150 (FIV) moves through the Golgi complex it is proteolytically cleaved by furin, a
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host cell protease, into its subdomains which remain associated only by non covalent
interactions44. The SU subdomain that is exposed on the surface of viral particles
determines the tropism of the virus, and interestingly the env gene is the gene with the
most sequence diversity among HIV-1 subtypes14.
Lentiviruses are complex retroviruses and as such are able to code for accessory
genes in addition to gag, pol and env through alternative RNA splicing patterns (Figure
2). These proteins serve a host of different essential functions and in many cases
deletions or mutations within these small non-enzymatic proteins can abolish viral
infectivity.
Following integration of the viral genome, one of the first genes to be expressed
in the HIV and SIV life cycle is the transcriptional activator or Tat protein. Tat is a
16kDa monomeric protein that is able to upregulate transcription of viral mRNA by
binding the transactivation response region (TAR) in the 5’LTR of the integrated proviral
DNA45. Tat is able to recruit the PTEF-b complex to the 5’LTR which in turn activates
RNA polymerase II and initiates transcription46. Studies have shown that the HIV-1 Tat
protein is able to trans activate transcription of the SIVmac239 genome but the
SIVmac239 Tat protein is unable to bind the HIV-1 TAR hairpin and activate mRNA
transcription47. FIV in contrast does not encode for Tat but instead has another gene that
is able to transactivate viral mRNA expression named orfA48. Basal transcription levels
before the binding of Tat to the HIV and SIV genomes are quite low, while FIV has a
much higher level of basal transcript being expressed even without orfA binding, yet
orfA is necessary for virus replication. The FIV genome does not contain a TAR region
in it’s 5’LTR like other lentiviruses and instead the binding of orfA has been mapped to
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the 3’ end of the U3 region, which results in a 14-30 fold increase over basal transcription
rates48.
Another crucial accessory gene that is expressed early in the lentivirus life cycle
is the regulator of expression of virus or Rev. Rev is a protein that is able to bind a
specific RNA sequence in the lentiviral genome49. After Rev is expressed, it is
translocated back into the nucleus to bind unspliced and partially spliced mRNA at the
Rev Response Element (RRE)50. The binding of Rev to the RRE facilitates export of
unspliced and partially spliced mRNA through the Crm1 nuclear export pathway. Studies
have also shown that Rev binding is necessary for maintaining the stability of the
unspliced and partially spliced mRNA and regulating translation51–53.
Some of the accessory genes that lentiviruses able to produce antagonize some of
the innate immune mechanisms that host cells use to restrict viral replication. One such
antagonist that exists in HIV, SIV and FIV is Vif. Both primate and non-primates
produce a apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3 or A3), a
family of cytidine deaminases that are able to convert cytidines to uracils 54–56. In
primates, A3G, A3H and A3F have been shown to restrict lentiviral replication by being
packaged within viral particles and creating crippling mutations in the viral genome
during reverse transcription and strongly restricting viral replication. In felines, A3Z has
been shown to restrict FIV replication in a similar manner57. Vif is able to block A3
activity by binding to it and triggering polyubiquitination which targets the A3 protein for
proteosomal degradation.
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Figure 2: Schematic of different RNA splicing patterns in Lentiviruses. (A) HIV-1 spliced transcripts
responsible for producing vif, vpr, vpu, tat rev, env and nef. (B) SIVmac239 spliced transcripts responsible
for producing vif, vpx, vpr, tat, rev, env and nef. (C) FIV 34TF10 spliced transcripts responsible for
producing vif, orfA, rev and env.
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Another host factor that restricts viral replication is tetherin, which inhibits the
budding of enveloped viruses at the plasma membrane. HIV-1 has evolved to encode
Vpu, an 81 amino acid protein that functions as a dimer and is able to antagonize tetherin
activity thus increasing budding of viral particles58. Although non-human primates and
felines also express tetherin, many (but not all) SIVs and FIV do not contain vpu. FIV env
has instead been shown to be involved in evading host tetherins and can effectively bud 59.
Some SIV strains that are vpu deficient have also developed env genes that are able to
antagonize tetherin but some SIV strains contain another accessory gene, Nef, that has
recently been discovered to antagonize tetherin60–62.
The Nef protein is one of the first proteins expressed during the infectious cycle
of HIV and SIV. Although it has no enzymatic activity, Nef has been shown to serve
many crucial roles in the primate lentivirus life cycle, and deletions in the Nef gene in
infected patients results in asymptomatic infection63,64. The CD8+ cytotoxic T cells of the
adaptive immune system help fight off intracellular pathogens by recognizing infected
cells through presentation of foreign antigens on Major Histocompatibility Complex 1
(MHC-1)65. HIV-1 Nef is able to downregulate the surface expression of MHC-1 through
two proposed models66. The first model proposes that Nef is able to induce the
endocytosis of cell surface MHC-1 while the second model postulates that Nef blocks the
transport of newly synthesized MHC-1 towards the host cell surface. SIV Nef has also
been shown to downregulate the surface expression of MHC-1 but it is not as well
characterized and some strains may downregulate expression through mechanisms
distinct from HIV-1 Nef. Another role that both HIV and SIV Nef are able to serve is to

13

decrease cell surface CD4 expression through endocytosis through an AP-2 and clathrin
dependant pathway67. Interestingly, FIV does not contain a Nef gene but studies have
shown that the orfA protein is also able to downregulate the expression of CD134, the
primary entry receptor used by FIV17.
Vpr is another multifunctional, non-enzymatic accessory protein that is highly
conserved in HIV and SIV. Vpr is a 14kDa protein that contains a nuclear localization
signal that is involved in helping it function as a chaperone for the translocation of the
pre-integration complex into the nucleus68. Furthermore, Vpr is able to induce cell cycle
arrest in the G2 phase, act as a transactivator for transcription from the LTR and
modulate T cell apoptosis. Some strains of SIV (SIVmac239) and HIV-2 also code for a
protein structurally similar to Vpr, known as Vpx. HIV-2, unlike HIV-1 is able to
transduce myeloid cells, which express a restriction factor sterile alpha motif and HD
domain-containing protein-1 (SAMHD-1). HIV-1 is restricted by SAMHD-1 in myeloid
cells, but Vpx is able to antagonize SAMHD-1 in HIV-2 and certain SIV strains, allowing
them to survive within these cells69,70. FIV does not code for Vpr, but the previously
mentioned orfA gene contains a nuclear localization signal and structure similar to that of
Vpr, and is implicated in induce cell cycle arrest in the G2 phase as well71.
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Figure 3 Visual Representation of Lentiviral Particle. The conserved viral proteins across gag, pol and
env are present to show the enzymes and structures packaged within a mature viral particle. Protruding
outward from the viral envelope is the env SU domain and embedded within the envelope is the TM trimer.
On the inner side of the envelope is the MA protein and further inside is the bullet shaped core made of CA
proteins, alongside the protease enzyme occupying space outside the core. Inside the core are the two
copies of viral RNA bound by IN and RT. Accessory proteins are not illustrated in this diagram but do get
packaged during the budding process.
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1.5 « Pre-integration Life Cycle»
The first step in all viral infections is entry into the host cell. The tropism of
lentiviruses are determined by the env gene, specifically the surface subdomain. In HIV
and SIV, the primary receptor used for virus entry is CD4 and thus HIV preferentially
infects CD4+ T-cell. The gp120 trimer is able to bind CD4 on the cell surface which
induces a conformational change putting the gp120 trimer in an “open” conformation.
Although FIV also preferentially infects CD4+ T cells, the primary receptor it uses is
CD13472. HIV and SIV both utilize co-receptors for cell entry, and following the gp120
conformational change, the V3 loop of gp120 is able to bind a chemokine coreceptor
which can be either CCR5 or CXCR473. FIV also utilizes a coreceptor for virus entry, but
only uses CXCR4 and no FIV that has tropism for CD134 and CCR5 has been
identified74,75. Transmitted HIV is typically CD4.CCR5 tropic but at later stages of
infection the viral envelope switches to use CXCR4 as the co-receptor76. CD4.CXCR4
tropic virus is rarely found in SIV infection, but has been shown in vitro. Interestingly,
certain strains of FIV are able to mediate cell entry using only the CXCR4 coreceptor,
indicating the gp100 trimer is in a more open conformation that allows interaction with
CXCR4, bypassing the requirement for initial CD134 binding74. Coreceptor binding then
exposes the hydrophobic fusion peptide of the TM domain which is able to insert itself
into the host cell membrane and mediate membrane fusion. Once the viral envelope and
cell membrane have fused, the viral capsid is released into the cell cytosol.
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Figure 4 The Process of Retroviral Reverse Transcription. (A) tRNA Lys3 binds the PBS. (B) Reverse
transcriptase begins synthesizing minus strong stop DNA and degrades RU5 region. (C) Newly synthesized
DNA strand switches to R region at 3’ end of viral RNA. (D) RT synthesizes DNA towards the PBS and
viral RNA is degraded except for PPT. (E)(F) PPT acts as a primer for DNA polymerase extension to
generate + strand DNA. (G) + Strand DNA strand switches to the PBS at the 3’ end of the – strand. (H)
DNA polymerase completes synthesis of proviral DNA in both directions.
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Packaged within the core of lentiviruses, is the reverse transcriptase enzyme that
fulfills the crucial role of converting the single stranded viral genomic RNA into double
stranded DNA (Figure 4)77. Initiation of DNA synthesis requires an RNA primer and for
the reverse transcription of lentiviral genomes cellular tRNA Lys3 is used. tRNA Lys3 is
packaged within the viral core and binds the primer binding site (PBS) within the 5’LTR
of the viral RNA, and from there RT begins synthesizing the minus strand DNA. RT
transcribes the DNA to the 5’ end of the viral genome to create what is referred to as the
minus strong stop DNA. RNAse H activity of RT is concomitantly degrading the R U5
region of the viral RNA as it is being reverse transcribed which causes the minus strong
stop DNA to bind to the 3’ R region of either the same viral RNA or the second packaged
copy and continue extending the minus strand DNA back towards the PBS. Again,
RNAse H degrades the rest of the remaining viral RNA except for the polypurine tract
(PPT) region that is resistant to RNAse H activity. The PPT lies slightly upstream of the
U3 region and serves as the primer to initiate synthesis of the positive stranded DNA. The
newly synthesized positive strand DNA extends towards the 3’ end of the viral genome
and then switches back to the complementary U5 region of the minus strand DNA at the
5’ end and the positive strand and minus strand DNA are synthesized toward both ends.
The newly synthesized proviral DNA must be integrated into the host
chromosomes before it can be transcribed to produce viral proteins. The integrase protein
is packaged along in the core of the viral particle and as the proviral DNA is being
synthesized, the viral capsid begins to come apart38. The first step in viral integration is 3’
end processing, wherein integrase binds the proviral DNA and recognizes a conserved
CA dinucleotide in each LTR at the 3’end of each strand and cleaves the site. This
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cleavage exposes a hydroxyl group at the 3’ end of each of the provrial DNA strands.
Integrase remains bound to the dsDNA alongside matrix and Vpr to form the preintegration complex (PIC) in HIV and SIV, which is then translocated into the nucleus of
the host cell78. FIV integrase also shuttles the dsDNA after 3’end processing into the
nucleus but the structure of the PIC isn’t as well characterized. Once inside the nucleus,
the next step in the integration process is strand transfer, a step that has been targeted for
many effective antiretroviral drugs. The exposed 3’OH groups at each end of the proviral
DNA attack a pair of phosphodiester bonds in the host DNA. The 2 nucleotide overhang
at each 5’end of the proviral DNA is removed and the gap in the host DNA is filled in by
host machinery and ligated to complete the integration process78.

1.6 « Post Integration Life Cycle»
Following integration into the cellular DNA, the viral DNA must be transcribed
into numerous transcripts necessary for the production of new viral particles. Lentiviruses
have evolved the ability to synthesize numerous proteins through their relatively small
genomes by using alternatively spliced transcripts. After integration, transcription is
initiated by the binding of host transcription factors to the 5’LTR. NF-kB, Sp1, and
TATA box binding protein (TBP) have binding sites within the LTRs of these
lentiviruses and initiate basal levels of transcription necessary for the production of fully
spliced transcripts that produce Rev and Tat during HIV/SIV infection, and Rev
alongside orfA in FIV infections51,79. As previously mentioned, Tat is able to
transactivate the transcription of HIV/SIV transcripts by binding to the TAR region of the
5’LTR. Tat binding to the TAR region of the 5’LTR results in the recruitment of pTEFb,
which is a kinase complex that contains Cyclin Dependent Kinase 9. CDK9 is able to
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recruit RNA polII and phosphorylate its C terminal domain, activating transcription.
pTEFb is also involved in enhancing the recruitment of TPB to the LTR promoter, also
increasing transcriptional activity46,47. Another function of Tat that has been shown is its
ability to promote chromatin re-modelling, making the region containing integrated
provirus more available for transcription. The transactivation of orfA on transcription
isn’t as well defined as Tat, but there is a similar increase on both mRNA transcription
and subsequently the expression of viral proteins48.
Transactivation of transcription from the 5’LTRs now leads to the production of
the partially spliced RNAs (approx. 4kb) that are responsible for encoding for Vif, Vpu
and Env in both HIV and SIV strains, as well as Vpx in HIV-2 and SIVmac23980. The
partially spliced RNA species in FIV code for Env as well as orfA71. The fully unspliced
mRNA is used for the translation of Gag and Gag-Pol, as well as serving as the genomic
RNA that is packaged within viral particles.
In eukaryotic cells, after post-transcriptional modification, only the mRNA
species that are fully spliced are exported through the nuclear membrane. In a similar
vein, this allows the early proteins in lentiviral infection such as Tat, Rev, Nef and orfA
be translated first since they are fully spliced transcripts that are able to be transported
through the nuclear membrane, whereas the partially spliced and unspliced transcripts are
trapped in the nucleus.
Lentiviruses have overcome this restriction by using the Rev protein to facilitate
nuclear export of partially spliced and unspliced mRNA species necessary for translation
of late proteins. Rev contains a nuclear localization signal that allows it to be transported
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back into the nucleus following translation in the cytosol51,81. Once in the nucleus, Rev is
able to bind the RRE that is present in the unspliced and partially spliced mRNAs. The
RRE is an RNA stem loop structure that is highly conserved in lentiviruses. In HIV and
SIV, the RRE sequence lies at the junction of the gp120 and gp41 domains within env,
while in FIV the RRE structure lies between the 3’end of env and the 3’LTR. Rev is able
to bind the RRE as a monomer and recruit cellular factors that allow the unspliced and
partially spliced mRNA to be transported through nuclear pores with the help of Crm1.
Following Rev/RRE binding, Crm1 binds the NES of Rev and additionally bridges
binding to RanGTP. This Rev/RRE/Crm1/RanGTP complex is able to interact with the
nuclear pore complex and be shuttled through the nuclear membrane with the help of
Nucleoporin 98 and Nucleoporin 21482.
Once the Rev/RRE/Crm1/RanGTP complex is in the cytosol, RanGAP1 and
RanBP1 bind the complex and induce the hydrolysis of RanGTP to Ran GDP. Following
this hydrolysis, Crm1 dissociates from Rev and goes back to the nucleus, allowing
importin-B to bind the NES of Rev82,83. The interaction between importin-B and Rev
disturbs the interaction with RRE and transports Rev back into the nucleus. The unbound
partially spliced or unspliced mRNA is now free to associate with host translational
machinery to synthesize viral proteins or become packaged by viral particles.
Once the unspliced mRNA is translocated into the cell cytoplasm, it is the
transcript responsible for synthesizing the gag and gag-pol polyproteins. The majority of
the time, translation that begins at the gag start codon continues until it reaches the stop
codon at the end of the gag ORF and produces the pr55 gag precursor that is
subsequently cleaved into MA, CA and NC84. As the ribosome approaches the
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overlapping region of the gag and pol ORFs it encounters a highly conserved RNA
structure known as the ribosomal frameshift signal (RFS)30,31. The RFS is the element
responsible for allowing for a frameshift event at about a 5% frequency permitting read
through of the gag stop codon and allowing for synthesis of the pr160 gag-pol
polyprotein. During a frameshift event, the ribosome approaches the RFS and stalls due
to the bulky hairpin structure that is formed. This stalling then causes the ribosome to slip
on the slippery sequence, which is UUUUUUU in HIV and SIV but GGGAAA in FIV,
and fall back into the -1 reading frame, allowing the ribosome to bypass the gag stop
codon and continue translating the rest of pol.
Following cleavage of the gag precursor, MA becomes myristoylated and targets
gag to the inside of the cell membrane, where the viral core is able to form and
subsequently bud along with pol, the accessory proteins and genomic RNA85,86. Some
had initially thought that viral RNA was necessary for the efficient formation of the viral
core, but studies showed that transfections with only gag resulted in particle formation
similar to wild type87. More recent studies however have been able to show that the
presence of viral RNA actually increases the production of viral particles, hinting at the
possibility that the NC/RNA complex serves as a point of nucleation for the production of
viral particles at the cell membrane88. Once the viral particle pinches off the cell
membrane carrying with it an envelope containing the SU and TM domains of env, the
particle undergoes the process of maturation in which protease begins cleaving the
immature gag-pol polyprotein into its substituents84. The ratio of gag to gag-pol has been
shown to be important for maturation since having too much protease present
significantly reduces the virus infectivity due to early and excessive cleavage 89.
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1.7 « Untranslated RNA Structural Elements»
The lentiviral genome contains regions that have no protein coding capacity but
are essential for replication and are highly conserved. The development of structural
modelling programs and newer RNA imaging techniques have been crucial in elucidating
the structures of these regions and how they impact both RNA-RNA interactions and
RNA-protein interactions (Figure 5)90,91. The region upstream of gag extending into the
5’LTR is the region that has been most extensively studied in HIV and has been ascribed
to have many functions. mFold was one of the first secondary structure prediction tools
that helped identify RNA stem loops within the 5’ leader of HIV and newer techniques
have been able to show more in depth tertiary structures of the same region in recent
years92,93.
As previously mentioned, the first highly structured RNA element that is in the
HIV and SIV 5’LTR is the TAR hairpin that acts as a docking site for Tat to transactivate
transcription. Directly downstream is the polyA stem loop that serves as the
polyadenylation signal that is crucial for mRNAs and this exists at the 3’end since this
region is a repeat94. Next is the PBS, where the tRNA Lys3 and RT can bind to initiate
the synthesis of minus strong stop DNA95,96.
Following the primer binding site is what has been described as the major
packaging signal: a series of four stem loop structures that have been implicated in the
efficient packaging of RNA. Extensive studies have been done on this region of the
genome to try and fully understand the interactions and sequences that are involved in the
packaging of specifically two copies of unspliced mRNA into budding viral particles.
These stem loops have been designated as SL1-SL496.

23

The RNA genome that is packaged within viral particles is a dimer, and SL1 has
been identified as the structural element in the 5’LTR responsible for initiating dimer
formation between two identical RNA copies and thus is also referred to as the Dimer
Initiation Site (DIS)97,98. DIS is a 49 nucleotide RNA hairpin structure that has a 9
nucleotide loop at the tip. Six of these 9 nucleotides are a palindrome which allows them
to Watson Crick base pair with the DIS of another unspliced mRNA strand. The
formation of the interaction is known as a kissing loop98. Following the formation of the
kissing loop, adjacent palindromic sequences are then able to also base pair with the
adjacent RNA strand to further stabilize the dimer formation. The 6 nucleotide
palindrome is highly conserved and only two hexanucleotide sequences have been
identified in infected patients dependent on subtype. Subtype B and D contain a
GCGCGC palindrome, while all other subtypes contain GUGCAC99. SIVmac239 also
contains a hexanucleotide palindrome sequence that is able to form a kissing loop with
another RNA strand, with the sequence GGUACC100.
SL2 in both HIV and SIV is a hairpin that contains the major 5’ splice donor sight
in the apical loop and is commonly referred to as the splice donor (SD). Studies have
shown that although the GGUG tetraloop of SD has a high affinity for binding the NC
domain of gag, it has been shown through mutational analysis that it is the GGUG
tetraloop at the apex of the SL3 (psi) hairpin that is responsible for binding NC to
package genomic RNA101. The presence of SD before SL3 provides an explanation for
the selective packaging of unspliced mRNA over the spliced mRNAs since the SL3 loop
would be removed. SL4 is the final stem loop in the major packaging signal and contains
the gag start codon at the base of the hairpin. SL4 has been shown to be involved in
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forming long range interactions to facilitate RNA conformations conducive to packaging
that will be discussed later92.
The structures of the 5’ leader of FIV has not been studied to the same degree as
primate lentiviruses, and therefore the functions of some of the stem loops have yet to be
fully elucidated. SHAPE analysis has shown that the secondary structure of the 5’ leader
in FIV is very different from that of primate lentiviruses 102.
In FIV, there are 9 stem loops upstream of the gag start codon whose functions
are not as well defined, and there is no definitive sequence that has been identified for
binding to the NC domain of gag to facilitate RNA packaging. As necessary for all
retroviruses, there is a PBS that exists between SL1 and SL2 where tRNA can bind to
initiate reverse transcription. The major splice donor falls between SL4 and SL5, just
slightly upstream of the gag start codon103.
Like all lentiviruses, FIV also packages dimerized RNA but interestingly the DIS
in FIV has been mapped to SL5 which falls within the gag ORF and contains a
palindromic sequence that has been hypothesized to initiate loose dimer formation in a
similar manner to SL1 in primate lentiviruses103.
The specific sequences as well as secondary and tertiary structures that form
within a strand of lentiviral unspliced mRNAs are not only important for RNA-RNA
interactions but RNA-protein interactions as well. The binding of Rev to RRE and Tat to
TAR are well documented and accepted RNA-protein interactions that are crucial for
replication, but recent studies have shown that even host restriction factors are able to
bind highly structured RNA sequences, such as APOBEC3Hs affinity for duplex RNA
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within the 5’UTR104,105. Other host proteins have been shown to recognize viral RNA in a
sequence dependent manner. APOBEC3G has been shown to bind preferentially to G
rich and A rich regions of RNA while Zinc Finger Antiviral Protein (ZAP) binds
preferentially to regions that are high in CG dinucleotides 106,107. One of the best examples
of the combination of the sequence and structure specific recognition of viral RNA is the
binding of NC to unspliced mRNA to facilitate packaging.
As previously mentioned, the zinc fingers, that are comprised of two conserved
CCHC motifs, within the NC domain of Gag is able to bind with high affinity to the G
rich loop of psi in the 5’UTR101. There is evidence that the binding of NC to psi helps
maintain and stabilize the dimerized form of unspliced mRNA that is known to be
packaged, but whether or not NC binds RNA before it dimerizes or after is still
debated108,109.
SIVmac239 NC is structurally very similar to that of HIV-1, and also contains 2
of the CCHC motifs that are capable of interacting with RNA. When experiments were
done to compare the NC and psi interactions across the viral species, HIV-1 NC and
SIVmac239 NC showed greater affinity for HIV-1 psi compared to TAR RNA, while
neither NC proteins showed a greater affinity for SIVmac239110. This would imply that
there is some other mechanism at play that is influencing SIVMac239 NC to
preferentially bind the unspliced mRNA to facilitate packaging. Although there are some
differences in the structure of FIV NC, the two zinc finger domains are still present, and
it is known that functionally they are very similar, but the binding specificity for FIV
RNA has not yet been effectively characterized28,111.
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1.8 « Models of RNA Packaging»
Although the RNA structural motifs and RNA-protein interactions involved in the
process of RNA packaging in HIV has been well documented, there still remains the
question of determining the destiny of unspliced mRNA for either translation or
packaging.
As is this case with many RNA strands, they are constantly in a structurally
dynamic state, meaning that the conformations they adopt can switch depending on their
surroundings or binding partners. Since the unspliced mRNA is used for translation of
Gag and Gag-Pol, it was initially hypothesized that two conformations existed: one that is
translationally competent while another that is conducive to being packaged within viral
particles and these two conformations have been termed the Long-Distance Interaction
(LDI) conformation and the Branch Multiple Hairpin (BMH) conformation, respectively
(Figure 5A)112.
The different elements within the 5’UTR that have been previously described can
only function if they form a conformation in which the sites of interactions are exposed.
In the BMH conformation, the AUG start codon of gag forms a duplex with the U5
region of the 5’ leader, allowing the DIS, SD and psi to form the correct hairpins. In this
state, the apex of the DIS stem loop is exposed, allowing the palindromic sequence to
form the kissing loop with another unspliced mRNA in the BMH conformation. By
allowing the unspliced mRNA to form a dimer, it was believed that this conformation
was the catalyst for sending this RNA species down the path of RNA packaging.
Additionally, by adopting the BMH conformation, ribosomes can not access the Gag start
codon since it is occluded.
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Figure 5 Dynamic Structural Models of HIV-1 5'UTR and Lentiviral RFS Structures. (A) The Long
Distance Interaction conformation in equilibrium with the Branched Multiple Hairpin conformation that
promotes RNA Packaging. (B) Comparison of the conformations proposed from the Summers lab with the
U5-DIS promoting translation and the U5-AUG and Three-way junction models promoting packaging. (C)
The different stem loops formed downstream of the slippery sequence of HIV-1, SIVmac239 and FIV
34TF10.
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In the LDI conformation, the DIS palindromic sequence instead forms a duplex
with the polyA hairpin. When the 5’UTR adopts this conformation, the DIS palindrome
is not able to interact with another unspliced mRNA to form a dimer. Additionally, in this
conformation, AUG does not form a duplex with U5, granting access to the ribosome to
begin translating the gag ORF. Interestingly, soon after these studies were done, the LDI
structure was disproven to be responsible for promoting translation of Gag and Gag-Pol,
since mutations that disrupted the equilibrium of the LDI/BMH structures did impact
RNA dimerization and packaging but had no impact on the production of Gag or GagPol113.
As technology has advanced, studies have been able to better elucidate the
conformations of unspliced mRNA in addition to getting a better understanding of the
localization of RNA-Gag interactions that facilitate genomic RNA packaging. In 2011
Summers’ group began using Nuclear Magnetic Resonance (NMR) imaging to detect the
structural elements that were at play during the process of RNA packaging92. In their
study, they proposed an alternate conformational switch in which the U5 region interacts
with the gag AUG to form packaging enhanced but translationally repressed
conformation. In 2015 the group expanded on this model and were able to generate 3D
images to reveal the tertiary structure of the packaging signal which adopts a three way
tandem junction structure and is quasi-tetrahedral in shape93. In this model, similar to the
BMH conformation, the U5-AUG duplex sequesters the Gag codon, as well as the splice
donor site within the three-way junction, to inhibit translation and mRNA splicing, while
DIS and psi are protruding outwards to promote dimerization and NC interaction (Figure
5B).
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1.9 « Discovery of GRPE»
Most of the major studies on RNA packaging have focused on the 5’UTR region
of the HIV genome due to the fact that mutations within the region will have no impact
on the production of viral particles. Studying RNA structural elements within the protein
coding region is more difficult due to the presence of multiple ORFs and therefore any
viral defects could be attributable to defective protein production. It is however crucial to
study the RNA structural elements within the protein coding sequence since they may
provide important insight into certain aspects of the viral lifecycle.
In 2013, Chamanian et al were able to show that indeed there exists an element
overlapping both the gag and pol ORF that is necessary for efficient packaging of
genomic RNA into viral particles114.
This finding was the result of attempting to optimize the infectivity of a
heterodiploid virus production system. One of the tools that the Arts lab uses for cloning
within full length HIV is yeast based homologous recombination115. Using a selectable
marker, one can easily insert specific sequences within the full-length HIV genome by
creating overhangs around that are homologous to the sequences flanking the target
sequence you are attempting to replace. By creating a double stranded break in the region
that is being replaced by the desired insert, yeast are able to recognize the regions of
homology around the insert and use double stranded break repair to stitch together the
insert and the vector. The issue that arose while using this system was that since the fulllength HIV genome contains LTRs, these would be recognized by the yeast as regions of
homology and instead the whole protein coding sequence of HIV would be kicked out.
To alleviate this problem, the 5’LTR was deleted upstream of the PBS and the resulting
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vector was termed near full length NL4-3 (nfl). This nfl construct was able to produce
viral particles since the full protein coding sequence was in the vector as well as package
its RNA since SL1-SL4 were also present. However, this viral particle was non-infectious
since the R U5 region was not part of the packaged RNA and therefore RT would be
unable to create minus strong stop DNA in the first step of reverse transcription. To be
able to study the infectivity of these different clones, a short complementing (cplt) vector
containing the R region of the 5’LTR extending just past the start codon of gag was cotransfected so that this short RNA could be packaged alongside the nfl RNA and initiate
reverse transcription to create minus strong stop DNA, which would then strand switch to
the nfl vector and complete reverse transcription. Based on Hardy Weinberg Equilibrium,
it was hypothesized that this complementation system would have 50% of the infectivity
compared to a vector that contained the full-length genome since 50% would be
homodiploid for one RNA or the other, while 50% would be heterodiploid and be able to
produce proviral DNA and infect target cells. The progeny virus actually turned out to
only be about 0.1% the infectivity of a transfected full length clone. This lead to
attempting to optimize the system by extending the RU5 cplt vector towards the 3’end of
the genome to identify at what point the hypothesized infectivity level would be reached.
Constructs that extended to the 3’ end of gag and further showed the expected level of
infectivity, and it was believed that this discrepancy in infectivity was due to inefficient
packaging of the complement vector which turned out to be true. Through mutational
analysis and fine mapping, the region responsible for this enhanced packaging was found
to overlap the ribosomal frameshift signal necessary for the production of the gag-pol
polyprotein. Deletion or perturbation of the structure of this stem loop resulted in a near
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50 fold decrease in the amount of packaged genomic RNA and a significant drop in virus
infectivity, and thus the region was termed the Genomic RNA Packaging Enhancer
Element.
As with the discovery of any functional element of a viral genome, it is important
to compare and contrast it to closely related ancestors as well as ones that are further
away on a phylogenetic tree. By doing so, you can get a better idea of the conservation of
such elements, the point of their evolution, as well as being able to narrow down the
specific function and pathway of the element. In the case of the GRPE, due to the high
similarity and elements involved in the RNA packaging process across lentiviruses, we
set out to test whether a GRPE element exists in SIVmac239 as well as FIV 34TF10, a
common strain of FIV.
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Chapter 2

2

« Methods»

2.1 « Yeast Based Homologous Recombination »
To introduce different mutations, and create large deletions, we harnessed the ability of
Sacharomyces Cerivisae to perform double stranded break repair on a transformed
plasmid by introducing a dsDNA insert with regions of homology flanking the location of
the break. The backbone of the constructs used for yeast cloning are based on pcDNA 3.1
(Invitrogen) with the addition of three specific genes. For replication of the transformed
plasmid within the yeast it must be recognized as an artificial chromosome, therefore an
autonomously replicating sequence (ARSH4) and a yeast centromere sequence (CEN6)
were inserted into the pcDNA 3.1 backbone to facilitate plasmid replication during
mitosis. Additionally, the β-isopropylmalate dehydrogenase (LEU2) gene was added to
the backbone as well to allow for selection and growth on leucine deficient growth
media.
The cut plasmid DNA and insert DNA were introduced into the yeast through the
lithium acetate transformation method. Yeast are initially grown in 50mL of yeast extract
peptone dextrose (YPD) media overnight in a shaking incubator at 30 C for 16 hours.
The yeast were then pelleted by centrifuging the culture at 4000g and resuspended in
1mL of sterile water. The yeast suspension was pelleted again by centrifugation by
spinning at 4000g for 5 minutes and resuspended in 400 L of TE/LiAc solution made of
1x TE (10mM Tris-Cl pH 7.5 and 1mM EDTA pH 8.0) and 1x Lithium Acetate (pH 7.5).
50 L of the yeast suspension is added to 3 g of linearized plasmid, 1 g of insert DNA,
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50 g of denatured Salmon Sperm DNA (Thermo Cat. No. 15632011) and 300 L of
polyethylene glycol (8 volumes 50% PEG400, 1 volume 10x TE and 10x LiAc). The
solution was incubated for 30 minutes at 30 C in a shaking incubator for one hour and
then heat shocked for 15 minutes at 42 C. Following heat shock, yeast were pelleted by
centrifuging at max speed for 10 seconds and resuspended in 100 L of water and plated
on appropriate media. Plates are allowed to grow 2-5 days until visible colonies formed.
Colonies are picked and inoculated in a 5mL culture overnight, then pelleted at
4000g. The pellet is resuspended in 200 L of breaking buffer (2% Triton X-100, 1%
SDS, 100 mM NaCl, 10 mM Tris-Cl, pH 8.0, 1 mM EDTA, pH 8.0) and added to 0.3g of
glass beads in a 1.5mL microcentrifuge tube and 200 L of
phenol/chloroform/isoamylalcohol. The mixture is vortexed for 2 minutes and
centrifuged for 5 minutes at 14000rpm at room temperature. 100 L of the aqueous phase
is transferred to a new 1.5mL microcentrifuge and mixed with 170 L of water, 30 L of
3M sodium acetate, 700 L of 100% ethanol and vortexed for 5 seconds. The mixture is
centrifuged for 10 minutes at 14000 rpm at room temperature, then pelleted and washed
with 700 L of 70% ethanol. The mixture is pelleted again, supernatant is removed and
the pellet is air dried for 5 minutes. The crude DNA pellet is resuspended in 20 L of
water and then transformed into Thermo Electrocompetent Stbl4 bacterial cells according
to manufacture protocol. Bacteria is plated on ampicillin plates and grown overnight. The
resulting colonies are then screened by either restriction digest, PCR or Sanger
sequencing.
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In the yeast cloning system, Orotidine-5'-phosphate decarboxylase is what serves
as the selectable marker for inserting different genes. URA3 is a catalytic enzyme that
allows for the growth of yeast on uracil deficient media. When yeast are being selected
for the insertion of the URA3 gene, they are grown on CMM media lacking leucine and
uracil (CMM-Leu-URA). URA3 also produces a toxic metabolite in the presence of 5Fluorootic acid, therefore when a gene is being inserted in place of the URA3 gene, yeast
are plated on CMM media with 5-FOA but lacking leucine (CMM-Leu+5FOA), to
negatively select for the desired product.

2.2 « Generation of SIVmac239 Heterodiploid System for
testing RFS Impact»
The two vectors required for the production of heterodiploid infectious
SIVmac239 virus were provided by Dr. Yong Gao (Figure 6A). The vector responsible
for produces all viral proteins was termed SIVmac239 nfl, which contained the
SIVmac239 genome from the PBS to the end of the 3’LTR was cloned into the pREC
backbone for use in the yeast recombination system. The second vector, which allows for
the initiation of reverse transcription, contains the SIVmac239 genome from the R region
in the 5’LTR to the end of the pol ORF in the pREC backbone and was called
SIVmac239 U5gag-pol. To evaluate the impact of the ribosomal frameshift signal on
RNA packaging within the SIVmac239 genome, the frameshift stem was deleted in the
U5gagpol vector. Using overlap extension PCR, primers were designed to create a 58
base pair deletion beginning at the slippery sequence (2351-2409). Two fragments were
generated in the first round of PCR amplification using an annealing temperature of 55 C
and an extension time of 1 minute with the following primer pairs: SIV delRFS fwd/SIV
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delRFS pol and SIV delRFS rev/SIV delRFS gag. The two fragments from the first round
of PCR are used as the template at equal copy number for the second round of PCR using
an annealing temperature of 58 C and extension time of 1 minute 30 seconds with the
SIV delRFS gag/SIV delRFS pol pair (Figure 6B). The U5gagpol vector and mutated
PCR product are digested at the BamHI SbfI cut sites and then ligated together using
NEB T4 Ligase according to the manufacturers protocol (Cat. No. M0202). The ligation
mixture was transformed into Thermofisher Electromax Stbl4 competent cells according
to manufacturers protocol, plated on LB Agar plates with ampicillin and colonies were
screened by Sanger sequencing.

2.3 « Making Large Scale Deletions in SIVmac239
U5gagpol»
To elucidate potential RNA structural elements in SIVmac239 that may impact
RNA packaging outside of the region of the ribosomal frameshift signal, URA3 was
inserted at different locations along the gag-pol ORF to disrupt any RNA structures
encompassing the region (Figure 6C). First, primers were used to amplify the URA3 gene
from the pREC URA3 vector as a template, containing 40bp overhangs with homologous
flanking the desired region of insert into the pREC SIVmac239 U5gag-pol vector. PCR
products were generated using Platinum Taq protocol and cycled with an annealing
temperature of 58 and an extension time of 2 minutes. BamHI was used to cut within the
gag gene and two different PCR products were used to insert URA3 to replace the
majority of gag or the 3’ half. Sbf1 and Bsu361 were used to make single cuts within pol
to insert URA3 at the 5’ third and in place of RT respectively. The cut plasmid was
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transformed into yeast along with the correct insert and plated on CMM-Leu-URA plates.
Colonies were screened to confirm correct insert by sequencing.
Yeast recombination was used to introduce the mutant ribosomal frameshift signal
in a near full length viral clone. Overlap extension PCR was used to introduce point
mutations into the ribosomal frameshift signal. Two 40bp primers were created that
contained the desired mutations that were reverse complements of each other. Two more
primers were created to amplify PCR products with the mutation primers. One PCR
product contains the mutated RFS at the 3’ end and one with the mutated RFS at the
5’end. These two products were added at equivalent copy number into another PCR
reaction using the 5’ and 3’ primers, allowing the two products from the first round of
PCR to anneal to each other and generate the full length insert containing the mutated
RFS. The target vector for cloning was obtained from the Viral ARTS library which was
a near full length construct containing URA3 in place of the p6 gene. The vector was cut
at the SacII site within the URA3 gene and transformed into yeast alongside the mutant
RFS insert and plated on CMM-Leu+5FOA plates. Colonies were picked after 72 hours
and screened by sanger sequencing.
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Figure 6 Cloning Schematic for Generation of Mutant SIVmac239 U5gagpol Vectors. (A) Visual
representation of the vectors used in the heterodiploid SIVmac239 system consisting of a U5gag-pol vector
and an nfl vector. (B) Approach to deleting RFS in U5gag-pol by digestion and ligation with PCR product
containing deleted RFS (C) Approach to creating U5gag-pol deletion vectors by amplifying URA3 with
primers containing overhangs flanking target sequence to introduce products through homologous yeast
recombination
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Figure 7 Schematic of Cloning Strategy to generate FIV 34TF10 vectors for evaluating impact of
RFS. (A) Binding of PCR primers (arrows) to generate fragments containing pREC homologous overhangs
required for cloning into pREC backbone using yeast based homologous recombination for FIV 34TF10
U5gagpol and FIV 34TF10 nfl. (B) Deletion of RFS in FIV 34TF10 U5gagpol using QuickChange XL II
Site Directed Mutagenesis.
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2.4 « Generation of FIV 34TF10 Heterodiploid System to
evaluate impact of RFS»
To generate the insert for the FIV U5gag-pol vector, primers were designed that
would amplify the FIV34TF10 molecular clone from the beginning of the R region in the
5’LTR to 273bp past the 3’ end of the gag ORF (Figure 7A). Each of the primers
contained a 40bp overhang homologous to the pREC backbone to allow for effective
yeast recombination. The pREC/URA3 vector contains only the URA3 gene, and
therefore was used as the target to insert the FIV U5gag-pol sequence into the pREC
vector. pREC/URA3 was cut with SacII and transformed into yeast alongside the FIV
U5gag-pol insert and plated onto CMM-Leu+5FOA to select for recombinants with
URA3 replaced by the insert sequence. Colonies were picked and screened by PCR.
To generate the FIV nfl vector capable of producing all viral proteins and also
transcribing an usnpliced mRNA capable of being packaged within virions, the insert was
amplified in two parts and yeast double recombination was used to generate the final
product. To generate the first fragment, primers were designed to amplify the FIV
34TF10 genome from directly after the 3’end of the U5 region to 2000bp into the pol
ORF, with the 5’ end of the fragment containing a 40bp overhang homologous to the
pREC backbone. The second fragment that was amplified beginning 1900bp into the pol
gene, providing 100 bp of homology between the two gragments, to the end of the 3’LTR
in addition to 40bp of overhang homologous to the pREC backbone. The two PCR
products were transformed alongside the SacII digested pREC/URA3 vector and plated
on CMM-Leu+5FOA plates to select for recombinants. The yeast will recombine the two
PCR fragmenets together due to the 100bp of homology within the pol gene and
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recombine the combined PCR fragment at each end due to the regions homologous to the
pREC background.
To test whether or not the RFS has any effect on the ability of an RNA strand to
be packaged, the FIV U5gag-pol vector was deleted from the slippery sequence to the
end of the RFS stem loop (Figure 7B). Primers were designed containing a 30bp deletion
(1881-1910) that would bind the region flanking the RFS and used with the Agilent
Quickchange XL II Site Directed Mutagenesis Kit (Cat. No. Cat. No. 200521) according
to manufacturer’s protocol. The mutated vector was transformed into ThermoFisher
Electromax Stbl4 cells and colonies were screened and confirmed by sequencing.

2.5 « Cell culture and transfection»
Human embryonic kidney 293T cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) with 10% fetal bovine serum (FBS) and 100 g/mL
penicillin/streptomycin. Cells were split at a ratio of 1:10 every 3 days. U87.CD4.CCR5
cells were grown in DMEM containing 10% FBS, 100 g/mL penicillin/streptomycin,
300 g/mL G418 and 1 g/mL of puromycin. U87 cells were split every 3 days at a 1:3
ratio. Crendell Reese Feline Kidney cells were also grown in DMEM with 10%FBS and
100 g/mL penicillin/streptomycin, and were split every 3 days at a ratio of 1:10.
To produce viral particles through transfection of human embryonic kidney 293T
cells, first 3x106 cells were plated on a 100mm cell culture dish and allowed to grow
overnight. Once cells were at about 60% confluency, cells were transfected. In each
experiment, the near full length plasmid and complementing 5’LTR construct were
transfected at an equal copy number adding to a total of 24 g of total DNA per reaction.
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The 24 g of plasmid DNA was added to 1mL of DMEM alongside 72 L of FuGENE 6
reagent (Promega) in a 1.5mL microcentrifuge tube, vortexed, incubated at room
temperature for 15 minutes and added to cells. At 8 hours post transfection, the culture
dish supernatant was removed and 17 mL of fresh media was added so as to remove any
unincorporated plasmid/liposome mixtures. Virus supernatant was harvest and purified at
48 hours post transfection.

2.6 « Virus Purification»
Following 48 hours post transfection, the 17mL of viral supernatant were
transferred to a 50mL conical tube and centrifuged at 1500 RPM for 10 minutes at 4 C to
pellet any cellular debris. The remaining supernatant was aspirated using a 60mL syringe
and clarified through a 0.45 M pore size filter. The remaining volume was transferred to
an 100KDa Amicon Ultra-15 Centrifugal Filter Unit (Cat. No. UFC910024), and
centrifuged at 3700 RPM for 12 minutes at 4 C. The volume remaining in the filter unit
was transferred to a new 1.5mL microcentrifuge tube, and topped up with PBS to fill to
the brim of the tube. The 1.5mL centrifuge tube was spun at 32000g for 1 hour. The
remaining supernatant was discarded, and the viral pellet was resuspended in 600 L of
PBS, aliquoted, and stored at -80 C until used.

2.7 « Reverse Transcriptase Assay»
Reverse transcriptase activity of viral harvests was used as a relative measure of
viral particles. 10 L of virus supernatant was added to 20 L of RT assay buffer (50mM
Tris-HCl, 5mM DTT, 5mM MgCl2, 150mM KCl, 0.05% NP-40 and oligo-dT poly-rA)
and incubated at room temperature for 30 minutes. Next, 5 L of RT buffer containing
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radioactive dTTP at a concentration of 4 Ci/mL was added per well and the mixture was
incubated at 37 C for 2 hours. Following incubation, 10 L of the mixture was spotted
onto DEAE filter mats, and allowed to dry for 10 minutes. The mat was subsequently
washed on a shaking incubator five times for 1x saline-sodium citrate buffer for 5
minutes each, followed by two, five minute washes with 85% ethanol. The filter mat was
then placed on a 65 heat block to dry for 15 minutes. Once dry, the filter mat was
exposed overnight on a Phosphor screen and imaged using the Bioquant 800
Phosphorimager and analyzed using ImageJ software.

2.8 « Infections for Real TCID50»
Infectivity assays for SIVmac239 and FIV 34TF10 were done using human
U87.CD4.CCR5 and CrFK cells respectively. Cells were plated in a 96 well plate at a
density of 4,000 cells per well and allowed to grow overnight. To measure the infectivity
of progeny virus, 300 L of virus supernatant was diluted 1:3 In a 96 well plate 7 times,
and 50 L of virus was added onto the plated U87 cells in triplicate. 24 hours post
infection, supernatant was removed and 150 L of fresh media was added. RT assays was
done on day 6 post infection, wells were scored + or – based on RT activity and the Reed
Meunsch method was used to calculate Real TCID50/mL.

2.9 « RNA Extraction and qRT-PCR»
Viral RNA was extracted from 140 L of concentrated virus supernatant using
Qiagen QIAmp Viral RNA Mini Kit (Cat. No. 52906) according to the manufacturer’s
protocol and eluted in 70 L of water. The extracted RNA was treated with DNAse to
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remove any residual plasmid DNA using the Ambion Turbo DNA-free Kit (Cat. No.
AM1907) following the manufacturer’s instruction.
To synthesize cDNA for quantification by qPCR, the viral RNA was subject to
reverse transcription PCR using AccuScript Hi-Fi Reverse Transcriptase (Cat. No.
200820) using the corresponding reverse qPCR primer. Initially, 5 L of RNA was added
to 2.0 L of 10mM dNTPs, 2.0 L of 10x AccuScript RT buffer, 1.0 L of the designated
RT-PCR primer at a concentration of 10 M as well as 7.25 L of water and subject to the
following cycling conditions: 88 C for 1 minute, 65 C for 10 minutes and 25 C for 5
minutes. While samples remained in the thermocycler at 25 C, added in order to each
sample was: 2 L of 100mM DTT, 0.25 L of RNAseOut and 0.5 L of AccuScript RT
enzyme. The reaction was then cycled at 42 C for 90 minutes, 70 C for 10 minutes and
held at 4 C.
The quantification of genomic RNA copy number was done through real time
qPCR using the TaqMan system. Primers and probes were acquired from EuroFins and
are found in Table 1. Each reaction contains 4 L of each primer at 10 M, 2 L of probes
at a concentration of 10 M, 8.25 L of ThermoFisher TaqMan FastAdvanced Mastermix
(Cat. No. 4444557), 1.25 L of water and 5 L of synthesized cDNA. Reactions for each
sample were run in triplicate alongside a 10 fold serial dilution of plasmid DNA with
known copy number to generate a standard curve for calculating RNA copy number from
cT values. The RT-qPCR reaction is then run on the QuantStudio Real Time PCR
platform using cycling conditions of: denaturation for 5 minutes at 95 C followed by 40
cycles of 95 C for 10 seconds and 62 C for 1 minute. The raw data was exported and a
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standard curve was generated, from which the Ct values of the experimental samples
were interpolated to get RNA copy number.

2.10 « Nuclear/Cytoplasmic RNA Fractionation»
300,000 cells were plated per well in a six well plate and allowed to grow
overnight. Once at ~70% cells were transfected for 24 hours with the necessary plasmids.
At 24 hours post transfection, cells were treated with 10 M Leptomycin B to block the
Crm1 pathway. 12 hours later, cells were harvested, pelleted at 1500g, washed with PBS
and pelleted again. The cell pellet was then resuspended in 5 pellet volumes of
cytoplasmic extraction (CE) buffer (10mM HEPES, 60mM KC, 1mM EDTA, 0.075%
NP40, 1mM DTT and 1mM PMSF adjusted to pH 7.6) and placed on ice for 3 minutes.
Next, the samples were centrifuged at 2000 RPM for 4 minutes to produce a pellet
containing the nuclei and the supernatant containing the cytoplasmic fraction. The
cytoplasmic fraction was moved to another tube and placed on ice. Next, the nuclei was
washed with 100 L of CE buffer without NP40 and pelleted again. Supernatant was
removed and the pellet was resuspended in 2 pellet volume of nuclear extraction buffer
(20mM Tris-Cl, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 1mM PMSF and 25%
glycerol adjusted to pH 8.0). The mixture was then incubated on ice for 10 minutes,
vortexing periodically and then transferred to a new tube. RNA was extracted from each
fraction using the ThermoFisher PureLink RNA Mini Kit (Cat. No. 12183020) according
to manufacturer’s protocol.

45

2.11 « Platinum Taq PCR Protocol»
All PCR reactions were done using the Thermofisher Platinum Taq DNA
polymerase kit (10966-018). Each reaction contains: 5 L of 10x Platinum Taq PCR
Buffer, 1.5 L of 50mM MgCl2, 1 L of 10mM dNTPs, 0.5 L of each forward and
reverse primer at a concentration of 20 M, 0.4 L of Taq Polymerase, 10ng of template
and water to bring the final reaction mixture to a total volume of 50 L. The PCR reaction
was subject to the following thermocycling conditions: initial denaturation for 2 minutes
at 95 C followed by 35 cycles of denaturation for 30 seconds at 95 C, annealing for 30
seconds at 58 C, extension at 72 C for 1min/kb of the final product length, followed by a
final 10 minute extension step at 72 C and hold at 4 C.
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Table 1 PCR Amplification and Mutation Primers
Primer Name

Primer Sequence (5’->3’)

Description

SIV delRFS fwd

TGGACCATGTTATGGCCAAATGCCCAGACAGACAGGCGGGG

RFS Deletion Primer Forward (1897-1916)

GCTGATGCCAACTGCTCCC
SIV delRFS rev

TAAAAAACCCGCCTGTCTGTCTGGGCATTTGGCCATAACA

RFS Deletion Primer Reverse (1792-1831)

SIV delRFS gag

GGAGCAGAAGTAGTGCCAGGA

Overlap Extension Forward Primer for 5' Fragment (10321035)

SIV delRFS pol

GTAAAGTAAAGGCAGTGTACTGCC

Overlap Extension Reverse Primer for 3' Fragment (10321035)

U5 del1 fwd

CTACGACCCAACGGAAAGAAAAAGTACATGTTGAAGCATGC

SIV URA3 Insertion 1 Forward (594-633)

CCGCGGAGATTGTACTGAGA
U5 del1 rev

AACAAGGACAACTTAGGGAGCCGTCAGGATCAGATATTGCC

SIV URA3 Insertion 1 Reverse (1204-1243)

CCGCGGAGATTGTACTGAGA
U5 del2 rev

CCAGTAATACTTCTACAGGCTGTCCTTCAATATGAGCAGTCT

SIV URA3 Insertion 2 Reverse (2069-2108)

GTGCGGTATTTCACACCGC
U5 del3 fwd

TGACAGAGGATTTGCTGCACCTCAATTCTCTCTTTGGAGGCC

SIV URA3 Insertion 3 Forward (2017-2056)

CGCGGAGATTGTACTGAGA
U5 del3 rev

GACCCCTTCCATCCCTGAGGCAGAACCTTATAAATGTATCCT

SIV URA3 Insertion 3 Reverse (2760-2799)

GTGCGGTATTTCACACCGC
U5 del4 fwd

CTGGATATAGGTGATGCATATTTCTCCATACCTCTAGATGCC

SIV URA3 Insertion 4 Forward (2657-2696)

CGCGGAGATTGTACTGAGA
U5 del4 rev

TAGCGGTGGTGTTGAGATAAAATCCCATTCCGGTATCCAGCT

SIV URA3 Insertion 4 Reverse (3556-3595)

GTGCGGTATTTCACACCGC
FIV U5gagpol fwd

TACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACG

FIV U5gagpol for pREC Insertion Forward (0-21)

AGTCTCTTTGTTGAGGACTT
FIV U5gagpol rev

AATAATATTAGGTATGTGGATATACTAGAAGTTCTCCTCGCA

FIV U5gagpol for pREC Insertion Reverse (2015-2037)

CAAACATTACCAAATATAC
FIV nfl Insert 1

TACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACT

fwd

TGGCGCCCGAACAGGGACTTG

FIV nfl Insert 1 rev

ATTGAGTACTCCTTCCATCTTTTG

FIV nfl First Fragment for pREC Insertion Forward (141-162)

FIV nfl First Fragment for pREC Insertion Reverse (4557-
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FIV nfl Insert 2

CAATTGAAAATAGGGCCTGGTATCTG

fwd
FIV nfl Insert 2 rev

FIV dRFS fwd

FIV dRFS rev

FIV nfl Second Fragment for pREC Insertion Forward (43444369)

AATAATATTAGGTATGTGGATATACTAGAAGTTCTCCTCGTG

FIV nfl Second Fragment for pREC Insertion Reverse (9236-

CGAAGTTCTCGGCCCGGATT

9258)

GTTGGCAAGGAAATAGAAAGAATTCGGGAGTGAATCAAAT

FIV Forward Primer for Site Directed Mutagenesis Deletion

GCAGCAAGCAGTAATGCCAT

of RFS (1636-1695)

ATGGCATTACTGCTTGCTGCATTTGATTCACTCCCGAATTCTT

FIV Reverse Primer for Site Directed Mutagenesis Deletion

TCTATTTCCTTGCCAAC

of RFS (1636-1695)
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Table 2 Primers Used for RT-qPCR
Primer Name

Primer Sequence (5’->3’)

Description

SIV U5F

CCTGGTCAACTCGGTACTCAA

qPCR Forward Primer for SIV U5gag-pol RNA

SIV U5R

GCCCTTACTGCCTTCACTCA

qPCR Reverse Primer for SIV U5gag-pol RNA

SIV U5 Probe

FAM-CTGTTAGGACCCTTTCTGCTTTGGG-BHQ1

qPCR Probe for SIV U5gag-pol

SIV nflF

GATGTCAGATCCCAGGGAGA

qPCR Forward Primer for SIV nfl RNA

SIV nflR

AGCTCCCTTGGTAGGTGGTT

qPCR Reverse Primer for SIV nfl RNA

SIV nfl Probe

HEX-TCCCACCTGGAAACAGTGGAGA-BHQ1

qPCR Probe for SIV nfl RNA

FIV U5F

TGAACCCTGTCGAGTATCTGTG

qPCR Forward Primer for FIV U5gag-pol RNA

FIV U5R

AGCAGCGTCTGCTACTGCTT

qPCR Reverse Primer for FIV U5gag-pol RNA

FIV U5 Probe

FAM-TTTTTACCTGTGAGGTCTCGGAATCC-BHQ1

qPCR Probe for FIV U5gag-pol RNA

FIV nflF

AAGACTCGCTATGTTGGCGT

qPCR Forward Primer for FIV nfl RNA

FIV nflR

GACCTCTAAATCAGCAGGCG

qPCR Reverse Primer for FIV nfl RNA

FIV nfl Probe

HEX-GGCGAGGATGCTGTAATCAACGCT-BHQ1

qPCR Probe for FIV nfl RNA
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Chapter 3

3

« Results »

3.1 « Deletion of RFS in SIVmac239 has no Impact on RNA
Packaging or Virus Infectivity»
Based on the presence of the GRPE element overlapping the RFS of HIV-1, we
used a similar system as Chamanian et al (2013) to identify whether this function is
conserved in the SIVmac239 genome. In the Chamanian paper, results showed that the
perturbation of the structure of the frameshift stem resulted in a defect in packaging.
Therefore, the frameshift stem of the RFS within the SIVmac239 genome was deleted
downstream of the slippery sequence in the U5gag-pol vector. This vector and the wild
type U5gag-pol vector were co-transfected in 293T cells with a nfl vector to produce viral
particles containing the two subgenomic RNAs (Figure 8A). 48 hours post transfection,
culture supernatant was harvested, concentrated and subject to radioactive RT assays to
measure the relative amount of viral particles. There was no significant difference in RT
activity in cell culture supernatant indicating that both conditions were producing nearly
the same amount of viral particles. Each condition had RT activity down to a dilution of
1:256 indicating a robust amount of virus production (Figure 8B).
The relative RT activity was used to normalize the amount of virus for
quantifying RNA copy number and infecting cells to measure infectious titers between
the different conditions. Viral RNA was extracted, reverse transcribed and subject to
qPCR using specific primers to measure the copy number of each subgenomic RNA that
was packaged within the viral particles. There was no significant difference between the
amount of WT U5gag-pol RNA and dRFS U5gag-pol RNA being packaged. Both of the
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U5gag-pol RNAs were packaged with similar quantities as the nfl RNA, falling within
the 106 to 107 copies/ L (Figure 9B, 9C).
In the heterodiploid genome system, viral particles that contain both the U5gagpol RNA and the nfl RNA are able to infect target cells. The U5gag-pol RNA initiates
reverse transcription to produce minus strong stop DNA that will then strand switch to
the R region of the nfl RNA to continue the reverse transcription process. Real TCID50
assays were done to measure the infectious viral titers in each condition by doing 8, 3
fold serial dilutions and infecting human U87.CD4.CCR5 cells. Infected wells were
identified by RT assay, scored + or – and the infectious titer was calculated using the
Reed Muench method. There was no significant difference in infectious titers between
cotransfection with WT U5gag-pol or dRFS U5gag-pol, which is reflective of the amount
of U5 RNA being packaged (Figure 9D). Thus, there is no RNA element in the RFS
downstream of the slippery sequence that impacts RNA packaging or infectivity in
SIVmac239.

3.2 « Deletions Across the gag-pol ORFs of SIVmac239
have no impact on RNA Packaging or Virus Infectivity »
Since the deletion of the frameshift stem in SIVmac239 did not have an impact on
its RNA packaging efficiency, there remained the possibility that an enhancement
element lied outside of the initially probed region. To address this, larger regions across
the U5gag-pol vector were replaced by the URA3 gene to disrupt any RNA structural
elements within the region. The URA3 gene was amplified with primers containing
overhangs homologous to the regions flanking the desired deletion location within the
U5gag-pol vector. Yeast recombination was used to insert these URA3 fragments into the
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U5gag-pol vector at the specified locations (Figure 8A) by creating single restriction
enzyme cuts within the region where deletion is desired. Four different deletions were
successfully made in the U5gag-pol vector with two deletions within the gag ORF and
two within the pol ORF, and named U5gag-pol del1-4.
In the same conditions as the comparison of WT U5gag-pol and dRFS U5gag-pol,
the new deletion mutants were cotransfected with SIVmac239 nfl and supernatant was
harvested and concentrated after 48 hours (Figure 8A). Following concentration, again,
one aliquot was used for RT assays to measure relative particle production between the
different conditions. Again, there was no significant difference in supernatant RT activity
between the cotransfection of WT U5gag-pol and the U5gag-pol deletion mutants (8B).
Like the dRFSU5gag-pol mutant, there was also no significant difference in packaged
RNA from the U5-gag-pol deletion mutants and the WT U5gag-pol mutant (Figure 9B).
The bipartite genome system was made so that deletions could be made within the
protein coding sequence of one RNA while the other would provide all proteins
necessary to produce viral particles. It is important to note that U5gag-pol del1 can’t
produce any gag, U5gag-pol del2 can’t produce capsid or nucleocapsid, U5gag-pol del3
can’t produce protease and U5gag-pol del4 can’t produce RT. The WT U5gag-pol vector
contains the intact protein coding sequence necessary for the production of the proteins
that can produce budding viral particles that could be detected by RT assays. Although
the U5gag-pol vectors are being packaged and thus travel through the cytoplasm, when
the WT U5gag-pol vector is co-transfected with the nfl vectors there is no increased
supernatant RT activity compared to the deletion mutants, indicating that the U5gag-pol
RNAs are not being used for translation and are only packaged as genomic RNA.
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As expected, with no difference in the amount of U5gag-pol RNA being packaged
in the deletion mutants, the virus infectivity is not significantly different from the WT
U5gag-pol vector (Figure 9D). In mutants such as U5gag-pol del1 and del2, during the
reverse transcription process, if there is recombination after the first strand switch event
within the pol region of the genome, the integrated provirus would be defective since
they would contain large deletions. The fact that there is no significant difference in the
infectivity levels between the deletion mutants and the WT U5gag-pol vector indicates
that recombination following the first strand switching event is negligible. Although there
are very high RNA copy numbers of genomic RNA in these samples, the infectious titers
were typically under 103 infectious units/mL which is relatively low (Figure 9D). This
low level of infection is most likely due to the use of the human U87.CD4.CCR5 that
does not have the macacque receptors that SIVmac239 has evolved to utilize.
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Figure 8 Production of Heterodiploid Genome Viral Particles. (A) Co-transfection of SIVmac239 nfl
and different mutant U5gag-pol vectors to produce viral particles. URA3 replaces del1 from position 6331204, del2 from 633-2069, del3 from 2056-2760 and del4 from 2696-3556. (B) Representative
autoradiograph of RT assay done on a dilution series of produced viral particles, 48h post transftion, to
measure relative particle count and bar graph illustrating RT activity relative to WT cotransfection
conditions, n=5.
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Figure 9 Packaged Genomic RNA and Infectivity of U5gagpol Deletion Mutants. (A) Schematic of
SIVmac239 vectors used for transfections and binding location of qPCR primers. (B) Copy number of
SIVmac239 U5gagpol RNA packaged within viral particles from cotransfections derived by RT-qPCR and
normalized by RT activity, n=5(C) Copy number of SIVmac239 nfl RNA packaged for each U5gagpol
vector co-transfection condition derived by RT-qPCR and normalized by RT activity, n=5. (D) Infectivity
of progeny virus for each U5gagpol vector co-transfection condition by Real TCID50 assay, n=2.
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3.3 « Generating Heterodiploid Genome System to
Evaluate Impact of RFS deletion in FIV34TF10»
The RNA structures that are implicated in packaging genomic RNA in the FIV
genome are not as well defined as those of primate lentiviruses, therefore we set out to
see if a GRPE like element also overlaps the FIV 34TF10 RFS. To setup the bipartite
genome system, primers were designed to amplify the FIV34TF10 genome and yeast
recombination was used to insert them into the pREC expression vector. To generate
FIV34TF10 U5gag-pol vector, the FIV34TF10 genome from the 5’ R region into just
past the gag orf was inserted into the pREC backbone. To create the FIV 34TF10 nfl
vector capable of producing viral particles, the genome downstream of the U5 region was
PCR amplified in two segments and yeast double recombination was used to insert both
segments into the pREC background. Next, the RFS of the FIV U5gag-pol vector was
deleted using site directed mutagenesis to be able to evaluate the impact the absence of
the structure had on genomic RNA packaging. The construction of these vectors was
done by Dr. Paul Wille.
Following the same experimental approach as for the SIVmac239 experiments,
the FIV U5gag-pol WT and dRFS vectors were co-transfected with FIV nfl in 293T cells
(Figure 11A). 48 hours post transfection supernatant was harvested, concentrated and
assayed for RT activity. There was no significant difference in the supernatant RT levels,
indicating that there was no difference in viral particle production levels as expected. RT
activity was detectable in the supernatant of both conditions even to a dilution of 1:256,
indicating a strong level of viral particle production (Figure 10B).
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The relative RT activity of the viral supernatants was used to normalize the
amount of input virus for infection of CrFK cells to quantify infectious viral titers
through Real TCID50 assays. Interestingly, the progeny virus showed extremely low
levels of infectivity in both conditions. There were near undetectable levels of
supernatant RT activity in the 1:3 dilution, which is contrary to what was expected based
on the very high levels of RT activity in the supernatant harvested from the 293T cell
transfection (Figure 10B). This result indicates that although there is a high level of viral
particles they are severely hindered in their ability to infect.
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Figure 10 Production and Infectivity of FIV 34TF10 in Heterodiploid Genome System. (A) Production
of viral particles by cotransfecting a U5gag-pol vector (WT or dRFS) alongside nfl. (B) Autoradiograph of
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Real TCID50 assay done to measure the infectivity of produced viral particles. (D) Graph comparing the
RT activity of viral particle produced post transfection vs post infection, n=3.
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Figure 11 RNA Packaging and Nuclear Export of FIV 34TF10 Heterodiploid Vectors. (A) Schematic
of vectors used to produce RNA measured in viral particles and nuclear/cytoplasmic fractions with qPCR
binding locations. (B) RNA copy number of subgenomic RNAs packaged within viral particles for different
cotransfection conditions, n=3(C) RNA copy number of subgenomic RNAs in nuclear and cytoplasmic
fractions of transfected 293T cells treated with Leptomycin B for inhibiting Crm1 nuclear RNA export,
n=2.
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3.4 « Defective Packaging and Export of FIV U5gag-pol
RRE Deficient Subgenomic RNA »
To address whether or not this defect in infectivity of produced viral particles was
caused by reduced RNA packaging, viral RNA was extracted, reverse transcribed and
subject to qPCR to measure the amount of each subgenomic RNA being packaged.
Although there was no significant difference in the amount of between the mutant and
WT U5gag-pol RNA, there was almost a 2 log decrease in the amount of packaged
U5gag-pol RNA, WT or dRFS, compared to the nfl RNA (Figure 11B). With such a low
amount of U5gag-pol RNA being packaged, there would be a large decrease in virus
infectivity since reverse transcription cannot be initiated and therefore explains the low
infection rates in both conditions.
In the construction of the U5 containing vectors throughout this study, as well as
much of Chamanian et al (2013) study, the RRE was not included. The RRE has been
shown to be required for the export of full length unspliced mRNA into the cytoplasm of
the cell through the Crm1 pathway. Full length unspliced mRNA is the RNA species that
is incorporated into viral particles, and thus to be packaged this RNA must be
translocated into the cytoplasm. In the case of our SIVmac239 U5gag-pol vector,
although there was no RRE, the RNA was being packaged at similar levels as the nfl
RNA indicating that it was being efficiently transported to the cytoplasm. To test whether
our FIV U5gag-pol vector was not being packaged due to nuclear export as a result of the
missing RRE, we compared the nuclear and cytoplasmic fractions of cells transfected
with both vectors to see if the U5gag-pol vector was trapped in the nucleus. 293T cells
were transfected with both the U5gag-pol vector (WT or dRFS) alongside the FIV nfl
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vector. At 24 hours post transfection, cells were treated with Leptomycin B, an inhibitor
of the Crm1 to confirm determine whether the vectors were being transported through the
Crm1 pathway. 36 hours post transfection cells were harvested, nuclear and cytoplasmic
fractions separated, and RNA extracted from each fraction. The RNA was reverse
transcribed and used for qPCR to quantify RNA copy number for the different RNA
species. As expected, there were comparable levels of FIV nfl RNA in the nuclear and
cytoplasmic fractions, and treatment with Leptomycin B resulted in almost a log decrease
in cytoplasmic FIV nfl RNA levels, confirming that the unspliced mRNA is being
transported through the Crm1 pathway (Figure 11C). In contrast, there is about a log
decrease in the amount of U5gag-pol RNA in the cytoplasm compared to the nucleus,
explaining the low amount of U5gag-pol RNA being packaged (Figure 11C). The
treatment of Leptomycin B resulted in slight increase of U5gag-pol RNA in the nuclear
fraction accompanied by a slight decrease in the cytoplasmic fraction. Together, this
result suggests that although the RRE is disposable for U5gag-pol vector for SIVmac239,
it is required for FIV 34TF10.
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Chapter 4

4

« Discussion »
Lentiviral RNA packaging has been studied for decades but the finer details of the

process still remain unclear. The overwhelming majority of the efforts to understand
lentiviral RNA packaging have been on HIV-1, specifically the RNA structures within
the 5’UTR. Extending these studies to other lentiviruses helps us better understand their
evolution while also providing better insight when designing tools and optimizing
different animal models.
The identification of the GRPE was an important discovery in the field of HIV-1
RNA packaging since it highlighted the importance of probing within the coding
sequence of lentiviruses for structures that serve multiple functions. The logical next step
was to look for similar elements in other lentiviruses to determine whether or not the
GRPE is a conserved element.
Since SIVmac239 is one of the most prevalent clones used for primate models of
infection and shares a fairly recent common ancestor with HIV-1, it was the first
candidate to test whether or not the GRPE element is conserved. The results showed that
no sequence within the gag-pol ORFs had any impact on the packaging of genomic RNA.
At this point, it is unlikely that any other RNA elements within the coding sequence of
SIVmac239 would have any impact on RNA packaging either since U5gag-pol RNA was
packaged at a similar level to the nfl RNA.
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HIV-1 and SIVmac239 only share about 50% sequence homology so it is
understandable that the RNA structures that form would differ not only in shape but to a
certain degree their functional capabilities. Chamanian et al (2013) showed that the
impact of the GRPE relied on the frameshift stem loop maintaining the correct
conformation and if mutations were done that still kept the stem loop structure intact,
there was no impact on RNA packaging. The frameshift stem loop of SIVmac239 is
distinct in size from that of HIV-1 therefore an RNA-RNA interaction or an RNA-protein
interaction with the frameshift stem loop might not be able to occur due to this difference
in stem loop size. The 5’UTR of SIVmac239 is also structurally distinct from HIV-1 and
although both regions have been considered to be the major determinants of packaging,
the exact process is most likely contains some differences. These differences could
account for the inability for any element within the coding sequence to enhance the
packaging efficiency of unspliced mRNA in SIVmac239.
SIVmac239 is very closely related to HIV-2, the significantly less pathogenic
counterpart to HIV-1. It would not be a stretch to think that HIV-2 also does not contain a
GRPE element due to it’s high sequence homology with SIVmac239, whereas SIVcpz
could very well have a GRPE like element since it is so closely related to HIV-1. Perhaps
the increased pathogenicity of HIV-1 compared to HIV-2 is that it has gotten better at
packaging it’s genome, therefore leading to greater infectivity. To address this
hypothesis, experiments can be done to calculate the absolute level of RNA per viral
particle to see if one virus packages their genome with greater efficiency than the other.
Our study relied on RT assays to get relative viral particle production between
transfection conditions, but by using p27 and p24 ELISAs, one could calculate the
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RNA/capsid ratio to get a more accurate measure of RNAs packaged per particle. Since
the RFS is a region that is responsible for two ORFs as well as promoting ribosomal
frameshifting, perhaps in the case of SIVmac239, the selective pressures of the host
immune system required specific mutations at the protein coding sequence that
outweighed the need for the region to enhance RNA packaging.
Although SIVmac239 did not exhibit any need for an additional RNA enhancing
element within the protein coding sequence, we still wanted to test the FIV RFS in the
same system. There was no difference in the amount of FIV U5gag-pol RNA that was
packaged when the RFS is deleted, however, there was a severe impairment of virus
infectivity, regardless of which U5gag-pol vector was cotransfected with FIV nfl. It
turned out that both U5gag-pol RNAs were being packaged at a quantity near two log
less than the FIV nfl RNA, thus limiting the template for which reverse transcription
could be initiated to produce proviral DNA. We postulated that this might be due to poor
export of the U5gag-pol RNA through the nuclear membrane into the cell cytoplasm due
to the absence of the RRE. Cells were transfected with both vectors and
nuclear/cytoplasmic fractionations were done to compare the RNA levels within each
fraction to see if the U5gag-pol vector was impeded in nuclear export. The results
showed a large reduction in cytoplasmic RNA of the U5gag-pol vector compared to the
nuclear fraction, while this reduction was not apparent in the FIV nfl RNA, indicating
that the RRE is most likely necessary for nuclear export and by proxy, RNA packaging.
This result was interesting since the SIVmac239 U5gag-pol vector that was used
was also missing the RRE element but was being expressed in the cell cytoplasm at the
same level as the SIVmac239 nfl RNA. Although this RNA was being expressed in the
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cytoplasm, it was not being translated since the amount of viral particles produced and
measured by RT activity did not decrease when gag was replaced with URA3 in the
U5gag-pol vector. This could imply that there are certain negative regulatory elements
within the gag-pol ORFs that inhibit protein translation in the absence of Rev/RRE
binding. One way of identifying these potential elements would be to use the U5gag-pol
URA3 deletions to insert GFP in frame in the different locations to simultaneously
remove the potential negative regulatory element and also have a phenotypic read out
(fluorescence).
The fact that the SIVmac239 U5gag-pol vector is packaged efficiently but not
translated could be beneficial in the design of lentiviral gene delivery systems. Many of
these systems rely on export elements such as that of the constitutive transport element
(CTE) of the Mason-Pfizer monkey virus in their transfer vector, but perhaps the
SIVmac239 system could provide an alternative. Before its application, an important
experiment that needs to be done is to add the 3’LTR to the U5gag-pol vector to see if it
retains efficient RNA export, since there could be potential negative regulatory elements
in the 3’LTR that suppress export of unspliced mRNA in the absence off the Rev/RRE
interaction.
Clearly, the FIV 34TF10 genome would not be as easily applied in the context of
this system. It is unclear why in the absence of RRE the SIVmac239 U5gag-pol is
exported but for FIV it is not. There are most likely negative regulatory elements that
exist that have not yet been identified that are implicated in trapping the RNAs in the
nucleus. The 5’ leader of the FIV genome vastly differs from those of primate
lentiviruses, and the function of many of these different structures has not yet been
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assigned. One possibility is that one of the structures downstream of the splice donor site
within the 5’UTR could be a negative regulatory element, since the elements upstream of
the splice donor exist on fully spliced, RRE deficient, transcripts that are efficiently
transported. Making point mutations within some of the stem loops in the 5’ leader that
would disrupt the structure in the FIV U5gag-pol vector and measuring the ability of
these mutants to be transported could shed more light on what other elements could be
involved in nuclear RNA transport. One study had shown that FIV gag localizes to the
nucleus after translation and acts as a shuttling protein for export of nuclear localized
proteins through the Crm1 export pathway. One idea that they had proposed based on
these findings is that perhaps NC interacts with genomic RNA within the nucleus and the
ribonucleoprotein is shuttled through the nuclear membrane and becomes packaged in
viral particles116. Our study disproves this theory since there are similar levels of FIV nfl
and FIV U5gag-pol RNA in the nucleus but this does not hold true in viral particles, and
therefore encapsidation of FIV genomic RNA does not initiate within nucleus of infected
cells. Unfortunately, the compromised nuclear export of the U5gag-pol RNA does not
allow us to conclusively claim that the RFS has no impact on RNA packaging.
Therefore, the logical next step is to clone the RRE back in to U5gag-pol RNA to
definitively see if the RFS plays any role. Efforts have been made to generate a U5
containing vector that spans from the 5’ R region to the RRE in FIV 34TF10 using the
yeast recombination system and including the RFS deletion. Unfortunately during the
recombination or transformation process, the U5 region gets deleted and yields negative
RT-qPCR data. RT assays done on transfection supernatant, however, show double the
amount of RT activity compared to just the RU5 gag-pol vectors (data not shown). This
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makes sense, since the transcript is being exported efficiently and being translated into
viral particles at a similar frequency as the U3 containing nfl vector, thus producing
double the amount of viral particles. In the future, other cloning strategies must be used
to try and incorporate the U5 region into these vectors for effective probing of the
genomic RNA and infectivity studies.
These studies not only shed light on the function, or lack thereof depending on the
context, of certain RNA structures in SIVmac239 and FIV 34TF10, but they also provide
some comparison to help narrow down how exactly GRPE enacts its function. Although
it was never our hypothesis, other studies have shown that the GRPE has no increased
binding affinity to HIV-1 NC than random RNA species. There could potentially be other
protein binding partners for the GRPE other than NC, since it has recently been shown
that full length unspliced mRNAs form granules with other host proteins such as DDX6
and ABCE1117. It is imperative that more studies are done to look into potential binding
partners by doing RNA pull downs followed by mass spectrometry.
Furthermore, there is also a strong possibility that the GRPE is able to improve
packaging efficiency through an RNA/RNA interaction. Perhaps the GRPE is involved in
a long range interaction with the 5’UTR that helps maintain a conformation that is more
conducive to RNA packaging instead of protein translation. One way to test this would be
to replace the SIVmac239 5’UTR with that of HIV-1, as well as swap the ribosomal
frameshift signals, and see if there is an increase in packaging efficiency, since
SIVmac239 NC is able to interact with HIV-1 psi and cross package it’s RNA. Another
possibility that requires exploration is that the GRPE could be involved in maintaining
the stability of RNA dimers. It has been well characterized that the DIS is responsible for
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forming the initial loose kissing dimer, but it is known that the RNAs form tighter
interactions when they are being packaged. There is a six nucleotide palindrome that
exists at the base of the P3 stem loop of the RFS in HIV-1, and there is evidence that a
pseudoknot can form at the RFS, which could potentially expose this region in a way that
could interact with the RFS of an adjacent RNA, possibly strengthening the dimer
interaction. More mutational analysis followed by salt titrations to measure dissociation
rates of the dimers would help elucidate or rule out this hypothesis.
In conclusion, the evolution of different lentiviruses has caused the divergence of
function in many of the RNA structural elements within their protein coding sequence.
This study highlights the importance of comparing and contrasting these elements across
lentiviruses to gain a better understanding of the role they play in their respect viral life
cycles.
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